Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal cisplatin HIPEC plus postoperative bidirectional chemotherapy after interval cytoreductive surgery in advanced ovarian cancer
2022-001107-41Phase 4Active
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cisplatin and paclitaxel in ovarian cancer, sponsored by Fundación para la Formación e Investigación Sanitaria. Primary endpoint: Postoperative morbidity and mortality. Started May 2022; status: active.
02
Drugs
cisplatinpaclitaxel
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2022-001107-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001107-41.